Jade Biosciences presents preclinical JADE301 data at EADV 2026

Jade Biosciences (JBIO) announced preclinical data characterizing JADE301, a half-life-extended anti-IFN-β monoclonal antibody in development for dermatomyositis, to be presented at EADV 2026.